Petros pharmaceuticals reports record revenue and gross profit during second quarter 2022

New york, ny / accesswire / august 15, 2022 / petros pharmaceuticals, inc. ("petros" or "the company") (nasdaq:ptpi), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended june 30, 2022. highlights include: reported net sales for q2 of $4.2 million achieved first positive quarter of adjusted ebitda over $200,000 announced positive results of over-the-counter (otc) label comprehension study for erectile dysfunction drug stendra® engaged massachusetts general hospital (mgh) in sponsored research agreement for tissue-specific oxygenation sensor device technology announced the company is pursuing the 505(b)(2) pathway for its investigational agent h-100 for peyronie's disease launched social media campaign with celebrity physician dr. drew pinsky.
PTPI Ratings Summary
PTPI Quant Ranking